{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:19:02Z","timestamp":1777627142312,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Borderline personality disorder (BPD) is a significant cause of morbidity with no approved pharmacological treatment. We assessed treatment trajectories of patients with BPD in real-world clinical practice to help identify treatment gaps.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, observational, cohort study used de-identified MindLinc electronic health records data from the Holmusk NeuroBlu database (Version 21R2) to analyse the treatment journey of patients with BPD (aged\u2009\u2265\u200912\u2009years with \u22651 diagnosis of BPD) that were prescribed pharmacological treatment within 14\u2009days of diagnosis (baseline) and had treatment data for \u226512\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of those prescribed pharmacological treatment at baseline, 1461 patients (16.1%) had 12\u2009months of follow-up data. Antidepressants were the most frequently prescribed medication at baseline (80.4%) either alone or in combination with other medication classes, followed by second-generation antipsychotics (SGAs), anxiolytics and mood stabilisers. In the 12\u2009months post-baseline, the most frequently recorded treatment pathway was a switch from 1 antidepressant to another. Sertraline (5.5%), fluoxetine (5%), and citalopram (5%) were the most-prescribed antidepressants; lamotrigine (24.9%), gabapentin (15.4%), and valproate (7.1%) were the most prescribed mood stabilisers; and quetiapine (22.1%) and aripiprazole (19.0%) were the most prescribed SGAs. Polypharmacy (defined as the prescription of\u2009\u2265\u20091 psychotropic medication) was observed in 83.1% of patients at baseline and increased with follow-up time and age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The high rates of polypharmacy observed suggest that current clinical practices may not fully align with treatment guidelines for BPD, and that patients with BPD experience a considerable treatment burden. Limitations of this study include the absence of psychotherapy data and the use of prescription records without information on treatment adherence. Nonetheless, the diversity of treatment patterns observed reflects the complex symptomatology of BPD and highlights the need to deepen our understanding of its neurobiology to improve pharmacological treatment strategies and translate to meaningful patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-026-07974-6","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:53:34Z","timestamp":1774022014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment trajectories of patients with borderline personality disorder prescribed pharmacotherapy: real-world insights from a retrospective observational study"],"prefix":"10.1186","volume":"26","author":[{"given":"Carissa","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"St.Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer B.","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily O. C.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joannas","family":"Yeow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kira","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Chee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayowa","family":"Oyesanya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"7974_CR1","unstructured":"APA. The America psychiatric association practice guideline for the treatment of patients with borderline personality disorder. 2023. https:\/\/www.psychiatry.org\/getmedia\/3ac9a443-4590-47e6-ad9b-0b2d1cff4d53\/APA-Borderline-Personality-Disorder-Practice-Guideline-Under-Copyediting.pdf. Accessed 20 June 2024."},{"key":"7974_CR2","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. APA. Diagnostic and statistical manual of mental disorders. 5th Edn. 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"7974_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11920-019-1040-1","volume":"21","author":"AC Videler","year":"2019","unstructured":"Videler AC, Hutsebaut J, Schulkens JEM, Sobczak S, van Alphen SPJ. A life span perspective on borderline personality disorder. Curr Psychiatry Rep. 2019;21:51.","journal-title":"Curr Psychiatry Rep"},{"key":"7974_CR4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00406-021-01332-1","volume":"272","author":"T Wagner","year":"2022","unstructured":"Wagner T, Assmann N, K\u00f6hne S, Schaich A, Alvarez-Fischer D, Borgwardt S, et al. The societal cost of treatment-seeking patients with borderline personality disorder in Germany. Eur Arch Psychiatry Clin Neurosci. 2022;272:741\u201352.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"7974_CR5","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.2147\/NDT.S423882","volume":"19","author":"D DiBenedetti","year":"2023","unstructured":"DiBenedetti D, Kosa K, Waters HC, Oberdhan D. Understanding patients\u2019 experiences with borderline personality disorder: qualitative interviews. Neuropsychiatr Dis Treat. 2023;19:2115\u201325.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"7974_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jpsychores.2012.05.001","volume":"73","author":"ML Fok","year":"2012","unstructured":"Fok ML, Hayes RD, Chang CK, Stewart R, Callard FJ, Moran P. Life expectancy at birth and all-cause mortality among people with personality disorder. J Psychosom Res. 2012;73:104\u201307.","journal-title":"J Psychosom Res"},{"key":"7974_CR7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/HRP.0b013e3182937116","volume":"21","author":"WW IsHak","year":"2013","unstructured":"IsHak WW, Elbau I, Ismail A, Delaloye S, Ha K, Bolotaulo NI, et al. Quality of life in borderline personality disorder. Harv Rev Psychiatry. 2013;21:138\u201350.","journal-title":"Harv Rev Psychiatry"},{"key":"7974_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00406-023-01655-1","volume":"274","author":"CA Sveen","year":"2024","unstructured":"Sveen CA, Pedersen G, Ulvestad DA, Zahl KE, Wilberg T, Kvarstein EH. Societal costs of personality disorders among treatment-seeking patients in Norway: the relative contribution of specific DSM-5 categories. Eur Arch Psychiatry Clin Neurosci. 2024;274:139\u201349.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"7974_CR9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/acps.13094","volume":"140","author":"LH Hastrup","year":"2019","unstructured":"Hastrup LH, Jennum P, Ibsen R, Kjellberg J, Simonsen E. Societal costs of borderline personality disorders: a matched-controlled nationwide study of patients and spouses. Acta Psychiatr Scand. 2019;140:458\u201367.","journal-title":"Acta Psychiatr Scand"},{"key":"7974_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.psc.2018.07.001","volume":"41","author":"J Paris","year":"2018","unstructured":"Paris J. Differential diagnosis of borderline personality disorder. Psychiatr Clin N Am. 2018;41:575\u201382.","journal-title":"Psychiatr Clin N Am"},{"key":"7974_CR11","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1521\/pedi_2012_26_093","volume":"28","author":"RL Tomko","year":"2014","unstructured":"Tomko RL, Trull TJ, Wood PK, Sher KJ. Characteristics of borderline personality disorder in a community sample: comorbidity, treatment utilization, and general functioning. J Pers Disord. 2014;28:734\u201350.","journal-title":"J Pers Disord"},{"key":"7974_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40479-019-0106-3","volume":"6","author":"S Simonsen","year":"2019","unstructured":"Simonsen S, Bateman A, Bohus M, Dalewijk HJ, Doering S, Kaera A, et al. European guidelines for personality disorders: past, present and future. Borderline Pers Disord Emot Dysregul. 2019;6:9.","journal-title":"Borderline Pers Disord Emot Dysregul"},{"key":"7974_CR13","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3109\/09540261.2011.606540","volume":"23","author":"P Tyrer","year":"2011","unstructured":"Tyrer P, Silk KR. A comparison of UK and US guidelines for drug treatment in borderline personality disorder. Int Rev Psychiatry. 2011;23:388\u201394.","journal-title":"Int Rev Psychiatry"},{"key":"7974_CR14","doi-asserted-by":"crossref","unstructured":"Paton C, Crawford MJ, Bhatti SF, Patel MX, Barnes TR. The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. J Clin Psychiatry. 2015;76:e512\u20138.","DOI":"10.4088\/JCP.14m09228"},{"key":"7974_CR15","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1176\/appi.ajp.24181010","volume":"181","author":"GA Keepers","year":"2024","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American psychiatric association practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry. 2024;181:1024\u201328.","journal-title":"Am J Psychiatry"},{"key":"7974_CR16","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.2174\/1570159X19666210610092958","volume":"19","author":"A Del Casale","year":"2021","unstructured":"Del Casale A, Bonanni L, Bargagna P, Novelli F, Fiasch\u00e8 F, Paolini M, et al. Current clinical psychopharmacology in borderline personality disorder. Curr Neuropharmacol. 2021;19:1760\u201379.","journal-title":"Curr Neuropharmacol"},{"key":"7974_CR17","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/S0140-6736(21)00476-1","volume":"398","author":"M Bohus","year":"2021","unstructured":"Bohus M, Stoffers-Winterling J, Sharp C, Krause-Utz A, Schmahl C, Lieb K. Borderline personality disorder. Lancet. 2021;398:1528\u201340.","journal-title":"Lancet"},{"key":"7974_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/10398562231153009","volume":"31","author":"AY Ning","year":"2023","unstructured":"Ning AY, Theodoros T, Harris K, Isoardi KZ. Overdose and off-label psychotropic prescribing in patients with borderline personality disorder: a retrospective series. Australas Psychiatry. 2023;31:195\u2013200.","journal-title":"Australas Psychiatry"},{"key":"7974_CR19","unstructured":"NICE. Borderline personality disorder: recognition and management. 2009. https:\/\/www.nice.org.uk\/guidance\/cg78. Accessed 25 Jun 2024."},{"key":"7974_CR20","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-021-00855-4","volume":"35","author":"G Gartlehner","year":"2021","unstructured":"Gartlehner G, Crotty K, Kennedy S, Edlund MJ, Ali R, Siddiqui M, et al. Pharmacological treatments for borderline personality disorder: a systematic review and meta-analysis. CNS Drugs. 2021;35:1053\u201367.","journal-title":"CNS Drugs"},{"key":"7974_CR21","doi-asserted-by":"publisher","first-page":"113556","DOI":"10.1016\/j.psychres.2020.113556","volume":"295","author":"LR Magni","year":"2021","unstructured":"Magni LR, Ferrari C, Barlati S, Ridolfi ME, Prunetti E, Vanni G, et al. Psychopharmacological treatment in borderline personality disorder: a pilot observational study in a real-world setting. Psychiatry Res. 2021;295:113556.","journal-title":"Psychiatry Res"},{"key":"7974_CR22","doi-asserted-by":"crossref","unstructured":"Stoffers-Winterling JM, Storeb\u00f8 OJ, Pereira Ribeiro J, Kongerslev MT, V\u00f6llm BA, Mattivi JT, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2022.","DOI":"10.1002\/14651858.CD012956.pub2"},{"key":"7974_CR23","doi-asserted-by":"crossref","unstructured":"Patel R, Wee SN, Ramaswamy R, Thadani S, Tandi J, Garg R, et al. NeuroBlu, an electronic health record (EHR) trusted research environment (TRE) to support mental healthcare analytics with real-world data. BMJ Open. 2022;12:e057227.","DOI":"10.1136\/bmjopen-2021-057227"},{"key":"7974_CR24","unstructured":"A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 1358894 once daily over 12 week treatment period in patients with borderline personality disorder [internet]. 2020. [cited 22 Jul 2025]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04566601."},{"key":"7974_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1162\/cpsy_a_00030","volume":"4","author":"SS Mukherjee","year":"2020","unstructured":"Mukherjee SS, Yu J, Won Y, McClay MJ, Wang L, Rush AJ, et al. Natural language processing-based quantification of the mental state of psychiatric patients. Comput Psychiatry. 2020;4:76\u2013106.","journal-title":"Comput Psychiatry"},{"key":"7974_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/YCO.0000000000000373","volume":"31","author":"V Starcevic","year":"2018","unstructured":"Starcevic V, Janca A. Pharmacotherapy of borderline personality disorder: replacing confusion with prudent pragmatism. Curr Opin Psychiatry. 2018;31:69\u201373.","journal-title":"Curr Opin Psychiatry"},{"key":"7974_CR27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12888-025-06716-4","volume":"25","author":"F Di Leone","year":"2025","unstructured":"Di Leone F, Steingrimsson S, Carlsen HK, Liljedahl SI, Sand P. Trends in pharmacological prescriptions and polypharmacy for personality disorders: a 10-year cross-sectional analysis of naturalistic data. BMC Psychiatry. 2025;25:314.","journal-title":"BMC Psychiatry"},{"key":"7974_CR28","doi-asserted-by":"crossref","unstructured":"Tennant M, Frampton C, Mulder R, Beaglehole B. Polypharmacy in the treatment of people diagnosed with borderline personality disorder: repeated cross-sectional study using New Zealand\u2019s national databases. BJPsych Open. 2023;9:e200.","DOI":"10.1192\/bjo.2023.592"},{"key":"7974_CR29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.euroneuro.2015.03.017","volume":"25","author":"R Bridler","year":"2015","unstructured":"Bridler R, H\u00e4berle A, M\u00fcller ST, Cattapan K, Grohmann R, Toto S, et al. Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. Eur Neuropsychopharmacol. 2015;25:763\u201372.","journal-title":"Eur Neuropsychopharmacol"},{"key":"7974_CR30","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/13651501.2019.1576904","volume":"23","author":"F Riffer","year":"2019","unstructured":"Riffer F, Farkas M, Streibl L, Kaiser E, Sprung M. Psychopharmacological treatment of patients with borderline personality disorder: comparing data from routine clinical care with recommended guidelines. Int J Psychiatry Clin Pract. 2019;23:178\u201388.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"7974_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1176\/appi.ajp-rj.2022.180207","volume":"18","author":"DE Curry","year":"2022","unstructured":"Curry DE, Richards BL. A brief review of Quetiapine. Am J Psychiatry Residents\u2019 J. 2022;18:20\u201322.","journal-title":"Am J Psychiatry Residents\u2019 J"},{"key":"7974_CR32","unstructured":"APA. Practice guideline for the treatment of patients with borderline personality disorder. APA; 2001."},{"key":"7974_CR33","unstructured":"National Collaborating Centre for Mental H. National institute for health and care excellence: guidelines. Borderline personality disorder: treatment and management. Leicester (UK): British Psychological Society; 2009."},{"key":"7974_CR34","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3109\/13651501.2011.590211","volume":"15","author":"C Haw","year":"2011","unstructured":"Haw C, Stubbs J. Medication for borderline personality disorder: a survey at a secure hospital. Int J Psychiatry Clil Pract. 2011;15:270\u201374.","journal-title":"Int J Psychiatry Clil Pract"},{"key":"7974_CR35","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1053\/comp.2001.19749","volume":"42","author":"MC Zanarini","year":"2001","unstructured":"Zanarini MC, Frankenburg FR, Khera GS, Bleichmar J. Treatment histories of borderline inpatients. Compr Psychiatry. 2001;42:144\u201350.","journal-title":"Compr Psychiatry"},{"key":"7974_CR36","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17:230.","journal-title":"BMC Geriatr"},{"key":"7974_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/JCP.0000000000000232","volume":"35","author":"MC Zanarini","year":"2015","unstructured":"Zanarini MC, Frankenburg FR, Reich DB, Harned AL, Fitzmaurice GM. Rates of psychotropic medication use reported by borderline patients and Axis II comparison subjects over 16 years of prospective follow-up. J Clin Psychopharmacol. 2015;35:63\u201367.","journal-title":"J Clin Psychopharmacol"},{"key":"7974_CR38","first-page":"199","volume":"9","author":"JM Guil\u00e9","year":"2018","unstructured":"Guil\u00e9 JM, Boissel L, Alaux-Cantin S, De La Rivi\u00e8re SG. Borderline personality disorder in adolescents: prevalence, diagnosis, and treatment strategies. Adolesc Health Med Ther. 2018;9:199\u2013210.","journal-title":"Adolesc Health Med Ther"},{"key":"7974_CR39","unstructured":"APA. Practice guideline for the treatment of patients with borderline personality disorder. Am Psychiatric Assoc Am J Psychiatry. 2001;158:1\u201352."},{"key":"7974_CR40","doi-asserted-by":"crossref","unstructured":"Kadiyala S, Chenoweth M, Watanabe JH. Off-label policy through the lens of trazodone usage and spending in the United States. Health Aff (Millwood) Scholar. 2025;3.","DOI":"10.1093\/haschl\/qxaf114"},{"key":"7974_CR41","doi-asserted-by":"crossref","unstructured":"Pardossi S, Cuomo A, Koukouna D, Pinzi M, Firenzuoli B, Fagiolini A. Methylphenidate in borderline personality disorder: assessing its therapeutic potential and limitations. Life (Basel). 2025;15.","DOI":"10.3390\/life15030380"},{"key":"7974_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/wps.21156","volume":"23","author":"F Leichsenring","year":"2024","unstructured":"Leichsenring F, Fonagy P, Heim N, Kernberg OF, Leweke F, Luyten P, et al. Borderline personality disorder: a comprehensive review of diagnosis and clinical presentation, etiology, treatment, and current controversies. World Psychiatry. 2024;23:4\u201325.","journal-title":"World Psychiatry"},{"key":"7974_CR43","doi-asserted-by":"crossref","unstructured":"Cloitre M, Garvert DW, Weiss B, Carlson EB, Distinguishing BRA, PTSD. Complex PTSD, and borderline personality disorder: a latent class analysis. Eur J Psychotraumatol. 2014;5.","DOI":"10.3402\/ejpt.v5.25097"},{"key":"7974_CR44","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.2147\/NDT.S192871","volume":"15","author":"L Weiner","year":"2019","unstructured":"Weiner L, Perroud N, Weibel S. Attention deficit hyperactivity disorder and borderline personality disorder in adults: a review of their links and risks. Neuropsychiatr Dis Treat. 2019;15:3115\u201329.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"7974_CR45","doi-asserted-by":"crossref","unstructured":"Lorenzi G, Baldwin DS. How should non-prescribed use of gabapentinoids be reduced in psychiatric practice? Hum Psychopharmacol Clin Exp. 2025;40:e70010.","DOI":"10.1002\/hup.70010"},{"key":"7974_CR46","doi-asserted-by":"publisher","first-page":"111478","DOI":"10.1016\/j.jclinepi.2024.111478","volume":"174","author":"J Fournier","year":"2024","unstructured":"Fournier J, Barret L, Khouri C, Naudet F, Boussageon R, Roustit M. The evidence base of the 10 most prescribed drugs in England, France, and the United States: a scoping review. J Clin Epidemiol. 2024;174:111478.","journal-title":"J Clin Epidemiol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-07974-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-07974-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-07974-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:54:48Z","timestamp":1777424088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-07974-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7974"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-07974-6","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the 1964 Declaration of Helsinki and its subsequent amendments. A waiver of HIPAA authorisation was obtained prior to study conduct and covers data originating from all sites represented. This study involves human participants but The NeuroBlu platform has received a waiver of authorisation for analysis of deidentified healthcare data from the Western-Copernicus Group (WCG) Institutional Review Board. Approval was granted by the WCG Institutional Review Board (The Holmusk Real-World Evidence Parent Protocol; IRB registration number 1-1470336-1; Protocol ID HolmuskRWE_1.0).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CW and JBD are employees of Boehringer Ingelheim Pharmaceuticals, Inc. SSR is an employee of Boehringer Ingelheim International GmbH. EOCP, JY, MO, KG, and BC are employees of Holmusk Technologies Inc. RP has received grant funding from the National Institute for Health and Care Research (NIHR301690), the Medical Research Council (MR\/S003118\/1), the Academy of Medical Sciences (SGL015\/1020) and Janssen, and consulting fees from Holmusk, Akrivia Health, Columbia Data Analytics, Clinilabs, Boehringer Ingelheim, Bristol Myers Squibb, Teva, and Otsuka.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"351"}}